why choose us

First received: August 10, 2022

Clinical Trial: Impact of Optical Genome Mapping in Acute Myeloblastic Leukemia

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Myeloblastic Leukemia

Study Type: OBSERVATIONAL


Official Title: Contribution of Optical Genome Mapping to the Prognostic Classification of Acute Myeloblastic Leukemia Evaluation of the Clinical Utility of DNA Optical Mapping in the Management of Acute Myeloblastic

Brief Summary: A retrospective study using a new technology will be performed: the Optical Genome Mapping (OGM) on acute myelogenous leukemia (AML) samples stored at the CRB-Cancer of the Bordeaux University Hospital and annotated in the DATAML clinical database.The main objective is to estimate the proportion of AML patients for whom OGM detects at least one additional abnormality compared to conventional techniques.This study will constitute an important step in the validation of COA as a reference technique for cytogenetic…

Read more